Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:6/12/2008

68,840 29,076

Long-term obligations 143 200

Accumulated deficit (120,577) (157,683)

Stockholders' equity 64,107 25,538

*does not include restricted cash

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future reven
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... University of Oregon chemist Geraldine Richmond, have tapped ... synthetic proteins called peptoid nanosheets that mimic complex ... detailed this week in a paper placed online ... the National Academy of Sciences -- is ... two-dimensional peptoid nanosheets that can be used in ...
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma ... a recommended approach for protecting personal data in ... researchers, patients and others. The document describes an ... information from CSRs and other related clinical trial ... The goal of the TransCelerate CSR Redaction ...
(Date:9/2/2014)... 02, 2014 Opertech Bio, Inc., ... efficient, cost effective approach to sensory evaluation, today ... by the U.S. Patent and Trademark Office, encompassing ... , “Opertech’s taste evaluation technology called Microtiter ... high throughput system for rapid characterization of taste ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... drug discovery and development services, cell lines, and reagents ... Feb. 26 The leading experts in ion channels ... discovery, development, and safety - are now united. ChanTest, ... validated cell lines, announced that it has acquired Rockville, ...
... the availability of Trade Alerts on stocks making news today. ... free by visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: ... Industries Ltd. (Nasdaq: TEVA ), Allergan Inc. (NYSE: ... ), Vertex Pharmaceuticals Inc. (Nasdaq: VRTX ) and ...
... announced today that it has received U.S. Food and ... using the Biomerix Biomaterial(TM), REVIVE acts as a tissue ... in a variety of soft tissue repair procedures, including ... procedures per year, inguinal hernia repair is one of ...
Cached Biology Technology:ChanTest Acquires Applied Cell Sciences 2ChanTest Acquires Applied Cell Sciences 3ChanTest Acquires Applied Cell Sciences 4Beacon Equity Issues Technical Trade Alerts on Drug Manufacturer Stocks: FRX, TEVA, AGN, CEPH, VRTX, ADLR 2Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures 2
(Date:9/1/2014)... television making us fat? An increasing amount of research ... consumption and a more sedentary lifestyle. Now, a new ... is alike. Some TV programs might lead people to ... that if you,re watching an action movie while snacking ... Tal, Ph.D. lead author on the new article just ...
(Date:9/1/2014)... Conventional wisdom has long held that corals ... reefs are passive organisms that rely entirely ... as nutrients and oxygen. But now scientists at ... in Israel have found that they are far ... into turbulent patterns that greatly enhance their ability ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Nature's tiny engineers 2Nature's tiny engineers 3A nucleotide change could initiate fragile X syndrome 2
... longest in the animal kingdom and they have largely ... scientists led by the University of Exeter have uncovered ... Africa and the results could have huge implications for ... the journal Current Biology, Dr Brendan Godley and an ...
... international team of scientists reported evidence, in a controversial cover ... more than 3.8 billion years ago--400 million years earlier than ... that team and two of the original authors will report ... , Craig E. Manning, lead author of the new study ...
... mouse is providing hope of a new treatment for ... transmission of serotonin in the brain. Serotonin is known ... sexuality. By breeding mice with an absence of TREK-1, ... of this research, which involved an international collaboration with ...
Cached Biology News:How satellite tracking revealed the migratory mysteries of endangered Atlantic loggerhead turtles 2UCLA scientists strengthen case for life more than 3.8 billion years ago 2UCLA scientists strengthen case for life more than 3.8 billion years ago 3UCLA scientists strengthen case for life more than 3.8 billion years ago 4UCLA scientists strengthen case for life more than 3.8 billion years ago 5Ever-happy mice may hold key to new treatment of depression 2
... Pig serum is collected from fasted Guinea Pigs. ... Citrate N-04: Heparin (Na) N-06: ... N-10: EDTA (Na) N-03: Alsevers ... N-09: K3EDTA N-11: Heparin ...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
... precipitation offers major advantages over other RNA precipitation ... protein or carbohydrates. It is the method of ... synthesis from RNA preparations. Note, LiCl precipitation may ... isolations. If the RNA is to be used ...
Biology Products: